


Abstract

Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib)

5 and a pharmaceutically acceptable carrier which is useful in a medicine



wherein the symbols, indices and substituents have the following meaning


10 $R^1 = \text{H, CN, NO}_2, \text{CF}_3, \text{F, Cl, Br, I, CH}_3$

$R^2 = \text{H, CN, NO}_2, \text{CF}_3, \text{F, Cl, Br, I, CH}_3, \text{Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl}$ and


either R^1 or R^2 must be H

$R^3 = \text{H, CN, NO}_2, \text{CF}_3, \text{F, Cl, Br, I, CH}_3, \text{Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl}$

15 then X is e.g.




or




20 with R^4 being H, CH_3 , CH_2CH_3

or




or




5

and Y being



or



10

or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.